Back to Search
Start Over
Negative effect of hepatitis in overall and progression-free survival among patients with diffuse large B-cell lymphoma
- Source :
- Infectious Agents and Cancer, Vol 13, Iss 1, Pp 1-7 (2018), Infectious Agents and Cancer
- Publication Year :
- 2018
- Publisher :
- BMC, 2018.
-
Abstract
- Background Hepatitis B virus (HBV) is one of the most prevalent and serious infections worldwide. HBV reactivation is a serious complication for lymphoma patients who are being treated with rituximab-containing regimen. Since the impact of HBV has not been fully evaluated on the prognosis of diffuse large B cell lymphoma (DLBCL), this study examined the effect of the hepatitis infection on the progression-free survival (PFS) and overall survival (OS) in patients with DLBCL who received rituximab-containing chemotherapy. Methods This retrospective cohort study was conducted at Princess Noorah Oncology Center, Jeddah by reviewing all medical records of 172 DLBCL diagnosed patients and recieved Rituximab-containing chemotherapy dated from January 2009 to February 2016. Results Out of 172 patients, 53 were found positive in hepatitis serology. The 12 of those were HBsAg-positive and 41 were HBcAb-positive. Hepatitis reactivation was observed in 1% of the patients (i.e., 2 out of 172) and both of them were HBsAg-positive. Thus, the risk of hepatitis reactivation among the HBsAg-positive patients was 17% (i.e., 2 out of 12). The predicted 3-year PFS for HBsAg-positive and HBcAb-positive were 52% (± 8%), while 76% (± 4) for HBsAg-negative and HBcAb-negative patients. On the other hand, the predicted 3-year OS for HBsAg and HBcAb-negative group is 93% (±3) while for HBsAg-positive and HBcAb-positive is 77% (±7), respectively. Conclusion The present study demonstrated a low HBV reactivation rate of 1% exclusively in 2 patients with HBsAg-positive status diagnosed with DLBCL and receiving R-CHOP chemotherapy.
- Subjects :
- 0301 basic medicine
Cancer Research
medicine.medical_specialty
HBsAg
Lymphoma
Epidemiology
medicine.disease_cause
Gastroenterology
lcsh:RC254-282
lcsh:Infectious and parasitic diseases
03 medical and health sciences
0302 clinical medicine
Internal medicine
hemic and lymphatic diseases
medicine
lcsh:RC109-216
Progression-free survival
Hepatitis
Hepatitis B virus
Hepatitis B virus reactivation
business.industry
virus diseases
Retrospective cohort study
Diffuse large B-cell lymphoma
medicine.disease
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
digestive system diseases
Regimen
030104 developmental biology
Infectious Diseases
Oncology
030220 oncology & carcinogenesis
business
Research Article
Subjects
Details
- Language :
- English
- ISSN :
- 17509378
- Volume :
- 13
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- Infectious Agents and Cancer
- Accession number :
- edsair.doi.dedup.....9ee8cb47cecf00443dd76e69c666abe0